Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations: A Descriptive Analysis From the US

Overview of attention for article published in Frontiers in oncology, February 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 34,770 followers.

RT @Latinamd: 6/15 #TumorBoardTuesday #LCSM 👩‍🏫Mini tweetorial 4 PD-L1 expression, tumor mutational burden, and response to immunotherapy…

RT @Latinamd: 6/15 #TumorBoardTuesday #LCSM 👩‍🏫Mini tweetorial 4 PD-L1 expression, tumor mutational burden, and response to immunotherapy…

RT @Latinamd: 6/15 #TumorBoardTuesday #LCSM 👩‍🏫Mini tweetorial 4 PD-L1 expression, tumor mutational burden, and response to immunotherapy…

RT @Latinamd: 6/15 #TumorBoardTuesday #LCSM 👩‍🏫Mini tweetorial 4 PD-L1 expression, tumor mutational burden, and response to immunotherapy…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.